- Shared test and research results on its new facelift thread brand Croquis
- Set up an exhibition booth and discussed expansion of partnership with global companies
- “Will accelerate the expansion to the global market in response to the growing demand in the cosmetic surgery market upon the brand reopening”

▲ Samyang Holdings Biopharmaceuticals Division participated in the Aesthetic and Anti-aging Medicine World Congress (AMWC) 2022, and promoted the excellence of its facelift thread brand Croquis.

The facelift thread brand Croquis from Samyang Holdings Biopharmaceuticals Division is accelerating its global marketing campaign targeting the brand reopening. The name croquis originates from a drawing technique that quickly sketches the outlines of a model and fittingly, the product promotes its ability to lift up the facial outlines quickly and naturally.

Samyang Holdings Biopharmaceuticals Division (President Lee Young-Joon) announced on April 6 that the company participated in the Aesthetic and Anti-aging Medicine World Congress (AMWC) 2022 held in Monaco from March 31 to April 2 local time to showcase the excellence of its facelift thread brand Croquis.

This year marks the 20th anniversary of AMWC, one of the two biggest aesthetic and anti-aging conferences in the world. It drew 10,000 aesthetic and cosmetic surgery specialists from 120 countries. Last year’s conference was organized in a hybrid format where in-person events were streamed live due to the COVID-19 pandemic. This year, the conference was organized around in-person events as intended.

The Biopharmaceuticals Division shared its test and research findings with South Korean and worldwide medical professionals, and set up an exhibition booth promoting Croquis’ quality and efficacy. In particular, on the first day of the congress on the 31st, Drs. Hema Sundaram and Henry Delmar, medical practitioners from the US and France, respectively, gave a presentation on the outcomes of international Croquis clinical trials, which drew a lot of attention.

A Croquis official said, “We participated in the conference in order to promote surgery techniques using Croquis and the clinical cases to medical professionals around the world, and to provide consultation services to global companies in order to increase the export volume and region. We will accelerate the expansion to the global market in response to the increasing demand in aesthetic and cosmetic surgery upon the endemic and resumption of economic activities.”

Croquis, a facelift thread brand from Samyang Holdings Biopharmaceuticals Division, targeted the global market right from the launch, releasing global case studies and research results while proving its efficacy and safety to the world through data. The company has signed sales contracts in 17 countries, including Japan and European countries, and is also seeking marketing approval in Brazil and Australia.

Meanwhile, the Biopharmaceuticals Division gained trust from the global cosmetic surgery industry by reasonable, data-based marketing, earning its second-mover advantage. While the conventional aesthetic facelift thread brands emphasize the change before and after the procedure, the Biopharmaceuticals Division is currently conducting research with key opinion leaders to secure clinical evidence to ensure safe and effective facelift procedures.